Clinical trials: Prostate Cancer Stage I
Metastatic Prostate Cancer
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.
- Trial name
- PETRANHA (NCT05367440)
- Testing
- AZD5305, Enzalutamide, Abiraterone Acetate
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 174 people
- Sponsor
- AstraZeneca
Malignant Solid Tumors, Lymphoma
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.
- Conditions
- Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03205176
- Testing
- AZD5153, Olaparib
- Where
- 4 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Castration-resistant Prostate Cancer
ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer
This is a safety, feasibility and pharmacokinetic study to confirm that the recommended safe dose and schedule of ModraDoc006/r (oral docetaxel with ritonavir) as determined in a previous phase I study is also safe and feasible…
- Trial name
- NCT03136640
- Testing
- ModraDoc006/r
- Where
- 4 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- Modra Pharmaceuticals
Prostate Cancer
Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with G-CSF may make tumor cells more sensitive to the chemotherapy drug and may kill…
- Trial name
- NCT00003183
- Testing
- filgrastim, mitoxantrone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Hope Cancer Institute, Inc.
Prostate Cancer
NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma.
- Trial name
- NCT02805894
- Testing
- NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Nanobiotix
Ovarian Cancer, Breast Cancer
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostatic Cancer
- Trial name
- NCT05740956
- Testing
- HS-10502
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of INR731 as a single agent and in combination with standard-of-care…
- Trial name
- NCT07570979
- Testing
- INR731, Enzalutamide, Abiraterone
- Where
- 13 sites in United States, Australia and 6 more
- Volunteers
- 208 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer, Breast Cancer
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- PETRA (NCT04644068)
- Testing
- AZD5305, Paclitaxel, Carboplatin
- Where
- 68 sites in United States, Australia and 12 more
- Volunteers
- 702 people
- Sponsor
- AstraZeneca
Prostate Cancer
Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents
This is a single blinded, randomized, cross-over design. Up to 12 patients will be randomly administered a single 10.0 mCi dose of 123I-MIP-1072 or 123I-MIP-1095 (study drugs).
- Trial name
- NCT00712829
- Testing
- 123-I-MIP-1072, 123-I-MIP-1095
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Healthy Subjects, Castration Resistant Prostate Cancer (CRPC)
A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects
A study to evaluate the bioavailability (BA) of a single oral dose of MDV3100 (enzalutamide) formulated as a solid spray dried tablet compared to oral liquid-filled capsules, and the safety and tolerability of oral formulations.
- Conditions
- Healthy Subjects, Castration Resistant Prostate Cancer (CRPC), Relative Bioavailability, MDV3100
- Trial name
- NCT01911741
- Testing
- MDV3100
- Where
- Germany
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Prostate Cancer
Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer
This was a multicenter, open-label, phase I/II study to evaluate the safety and tolerability, radiation dosimetry and pharmacokinetic characteristics, and efficacy of [177Lu] Lu-XT033 injection in patients with metastatic…
- Trial name
- NCT06081686
- Testing
- Phase I:[177Lu]Lu-XT033 Injection, Phase II:[177Lu]Lu-XT033 Injection
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Sinotau Pharmaceutical Group
Stage III Prostate Carcinoma, Stage IV Prostate Carcinoma
Dose Finding Safety Study of VAL201 in Cancer Patients
Dose finding safety study of VAL201 in cancer patients.
- Trial name
- VAL201-001 (NCT02280317)
- Testing
- VAL201
- Volunteers
- 12 people
- Sponsor
- ValiRx Plc
Advanced and/or Metastatic Solid Tumours
A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions
CB307 is a trispecific Humabody® targeting CD137; PSMA; and human serum albumin (HSA) undergoing Phase 1 assessment in patients with PSMA+ solid tumours.
- Trial name
- NCT05836623
- Testing
- Radiolabelled CB307, CB307
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Crescendo Biologics Ltd.
Cancer
Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer
This is a 2-arm randomized controlled study comparing how effective two therapeutic digital software devices are at improving anxiety and other indicators of psychological and physical health in patients with cancer.
- Trial name
- RESTORE (NCT05227898)
- Testing
- Device: Attune™, Device: Cerena™
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- Blue Note Therapeutics
CLL, Solid Tumor, Adult
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
The goal of this clinical trial is to test the safety and preliminary efficacy of a new drug, KLS-1, in adults with different types of solid tumors and chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06506643
- Testing
- Zinc-64 Aspartate
- Where
- 2 sites in Ukraine
- Volunteers
- 36 people
- Sponsor
- Vector Vitale LLC
Hormone Refractory Prostate Cancer
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of single-agent AT-101 in men with hormone-refractory prostate cancer.
- Trial name
- NCT00286806
- Testing
- AT-101
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Ascenta Therapeutics